$1.200
-0.029 (-2.44%)Al cierre
Noticias de TLPH
Eventos de TLPH
Vince Angotti: Nafamostat Study Progressing Well
Cash and investments balance was $21.1M as of March 31. "In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady enrollment, we have well exceeded this level, and continue to expect study completion later this year," stated Vince Angotti, CEO. "Our clinical study sites and principal investigators remain focused on enrollment and delivering a high quality study as they are eager for a potential alternative anticoagulant for Continuous Renal Replacement Therapy. The investor and analyst event held in March also highlighted the need for an alternative, given the disadvantages of the currently used products, heparin and citrate. If approved, we continue to believe nafamostat will fill an unmet need in the market as a regional anticoagulant for CRRT".
Talphera Files to Sell 639,931 Shares of Common Stock
Talphera files to sell 639,931 shares of common stock for holders
Trump Claims US-Iran Talks Boost Markets
The major averages closed sharply higher after President Donald Trump said the U.S. and Iran have held talks and that he was ceasing plans to attack Iranian power plants and energy infrastructure. Of note, however, AP reported that two Iranian semi-official news agencies close to the paramilitary Revolutionary Guard claim that there have been no such negotiations. Following Trump's comments, oil prices sharply pulled back, while shares of airlines and cruise lines advanced.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Elon Musk plans to start his Terafab project, which will be run by Teslaand SpaceX, in Austin, Texas,U.S. Senators have introduced a bill aiming to ban sports bets on prediction markets,Activist investor Elliot Management has built a stake in Synopsys,Palantir'sMaven AI system will be adopted by the Pentagon as a core military system,Delta Air Linessaid thatat New York's LaGuardia Airport following the collision of an Air Canadaplane into a Port Authority firetruck that resulted in two pilot deaths2. WALL STREET CALLS:MongoDBto Outperform from Neutral at MizuhoRaymond JamesAeroVironmentafter share underperformanceValvolineto Buy at StifelMacquarieXPengwith 2026 volume growth "no guarantee"William Blaira handful of names in infrastructure software, including Backblaze, N-able, GitLaband Dropboxto Underperform3. AROUND THE WEB:Gileadis near a deal to buy Ouro Medicines for up to $2B, FT reportsOpenAI offers buyout firms sweeter deals than Anthropic, Reuters reportsSonyis close to a deal to sell a majority stake in its home entertainment business to Chinese rival TCL Electronicsin a deal that may be valued at about $1B, Bloomberg reportsUnited Airlinesplans to cut additional unprofitable flights over the next two quarters as it braces for sustained high jet fuel prices tied to the Iran war, despite strong travel demand and higher fares, Reuters saysMP MaterialsCEO James Litinsky has repositioned the company as a key U.S. rare earths supplier amid rising geopolitical tensions and Chinese export restrictions, CBS News reports4. MOVERS:Apogee Therapeuticsgained afterfrom Phase A of its Phase 2 APEX trial of zumilokibartTeraWulfadvanced after Areteof the stock with a Buy ratingEstee Lauder (EL) dropped after Puig Brandsconfirmed that it is in discussions regarding a potential business combination with the companyEquinordeclined after230MW Esquina do Vento onshore wind complex from VestasPG&Efell after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:Talphera, with EPS higher year-over-yearOndasreportedand provided guidance for FY26 and Q1Solo BrandsprovidedCabaletta Bio, with EPS beating consensusChina Petroleum and Chemicalreported, with EPS and revenue lower year-over-yearINDEXES:The Dow rose 631.00, or 1.38%, to 46,208.47, the Nasdaq gained 299.15, or 1.38%, to 21,946.76, and the S&P 500 advanced 74.52, or 1.15%, to 6,581.00.
Trump Claims US-Iran Talks, Oil Prices Pull Back
The major averages were sharply higher near noon after President Donald Trump said the U.S. and Iran have held talks and that he was ceasing plans to attack Iranian power plants and energy infrastructure. Of note, however, AP reported that two Iranian semi-official news agencies close to the paramilitary Revolutionary Guard claim that there have been no such negotiations. Following Trump's comments, oil prices are sharply pulling back, while shares of airlines and cruise lines are advancing.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Elon Musk plans to start his Terafab project, which will be run by Teslaand SpaceX, in Austin, Texas,U.S. Senators have introduced a bill aiming to ban sports bets on prediction markets,Activist investor Elliot Management has built a stake in Synopsys,Palantir'sMaven AI system will be adopted by the Pentagon as a core military system,Despite Trump's claims of productive talks with Iran, two Iranian semi-official news agencies close to the paramilitary Revolutionary Guard claimed that there had been no such negotiations,2. WALL STREET CALLS:MongoDBto Outperform from Neutral at MizuhoRaymond JamesAeroVironmentafter share underperformanceValvolineto Buy at StifelMacquarieXPengwith 2026 volume growth "no guarantee"William Blaira handful of names in infrastructure software, including Backblaze, N-able, GitLaband Dropboxto Underperform3. AROUND THE WEB:Sonyis close to a deal to sell a majority stake in its home entertainment business to Chinese rival TCL Electronicsin a deal that may be valued at about $1B, Bloomberg reportsUnited Airlinesplans to cut additional unprofitable flights over the next two quarters as it braces for sustained high jet fuel prices tied to the Iran war, despite strong travel demand and higher fares, Reuters saysMP MaterialsCEO James Litinsky has repositioned the company as a key U.S. rare earths supplier amid rising geopolitical tensions and Chinese export restrictions following tariffs imposed by Donald Trump in 2025, CBS News reportsA former Metaexecutive will lead the ad push at OpenAI, WSJ reportsAn Air Canada Expressflight operated by Jazz Aviation LP collided with a fire truck shortly after landing at LaGuardia Airport, killing both pilots among the 76 people on board, Bloomberg reports4. MOVERS:Apogee Therapeuticsgains afterfrom Phase A of its Phase 2 APEX trial of zumilokibartTeraWulfincreases after Areteof the stock with a Buy ratingTower Semiconductorhigher in New York after demonstrating a 400 Gbps/lane dataEquinorlower in New York after acquiring the ready to buildonshore wind complex from VestasPG&Efalls after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:Talphera, with EPS higher year-over-yearOndasand provided guidance for FY26 and Q1Solo BrandsCabaletta Bio, with EPS beating consensusChina Petroleum and Chemical, with EPS and revenue lower year-over-yearINDEXES:Near midday, the Dow was up 1.61%, or 733.01, to 46,309.99, the Nasdaq was up 1.40%, or 302.85, to 21,950.46, and the S&P 500 was up 1.31%, or 85.22, to 6,591.70.
Talphera Reports Cash and Investments of $20.4M
Reports cash and investments of $20.4M at December 31, 2025. "Earlier this month, we communicated reaching the 35-patient enrollment mark in the 70-patient nafamostat registrational study for CRRT. Since then, we have added two more target profile clinical sites, and are continuing to enroll patients at a pace to enable completion of the study later this year," stated Vince Angotti, CEO of Talphera. "Our target profile clinical sites and principal investigators remain highly motivated, driving over 90% of enrollment to date, and they are excited by the prospect of having nafamostat potentially approved for use during CRRT, given their dissatisfaction with the current anticoagulants currently being used for CRRT. Later today, we are hosting a live virtual investor and analyst webcast where you will hear directly from two principal investigators in the NEPHRO CRRT registrational study and their experiences with CRRT, the currently available anticoagulants for CRRT, and how they see nafamostat potentially filling an unmet need."
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.